Treatment with Zoledronic Acid Ameliorates Negative Geometric Changes in the Proximal Femur following Acute Spinal Cord Injury
- 240 Downloads
Acute spinal cord injury is associated with rapid bone loss and an increased risk of fracture. In this double-blind, randomized, placebo-controlled trial, 17 patients were followed for 1 year after administration of either 4 or 5 mg of zoledronic acid or placebo. Bone mineral density (BMD) and structural analyses of the proximal femur were performed using the hip structural analysis program at entry, 6 months, and 12 months. The 17 subjects completed 12 months of observation, nine receiving placebo and eight zoledronic acid. The placebo group showed a decrease in BMD, cross-sectional area, and section modulus and an increase in buckling ratio at each proximal femur site at 6 and 12 months. Six months after zoledronic acid, BMD, cross-sectional area, and section modulus increased at the femoral neck and intertrochanteric regions and buckling ratio decreased consistent with improved bone stability. However, at 12 months, the femoral narrow-neck values declined to baseline. In contrast to placebo, the intertrochanteric region and femur shaft were maintained at or near baseline through 12 months in the zoledronic acid-treated group. Urine N-telopeptide excretion was increased at baseline and declined in both the placebo and treatment groups during the 12 months of observation. We conclude that a single administration of zoledronic acid will ameliorate bone loss and maintain parameters of bone strength at the three proximal femur sites for 6 months and at the femur intertrochanteric and shaft sites for 12 months.
KeywordsBone loss Spinal cord injury Zoledronic acid Dual-energy X-ray absorptiometry Hip structural analysis
We thank Dr. Peter Richardson, Head of Development at Novartis Pharmaceuticals, Japan, for his assistance in the initiation of the study and Dr. Uri Liberman, University of Tel Aviv, for editorial assistance. Funding for this work was provided by the National Space Biomedical Research Institute and Novartis Pharmaceuticals, Inc.
- 1.LaPlante MP (1988) Data on Disability from the National Health Interview Survey 1983–1985. US National Institute on Disability and Rehabilitation Research, Washington DCGoogle Scholar
- 12.American Spinal Injury Association, International Medical Society of Paraplegia (2000) International Standards for Neurological Classification of Spinal Cord Injury, rev, 5th ed. Barcelona, Sept. 7, 1992Google Scholar
- 13a.Physicians’ Desk Reference, 58th ed. (2004) Thomson Healthcare, Thomson PDR, Montvale, NJGoogle Scholar
- 33.Reid IR, Bown JP, Burckhardt P, Horowitz Z, Richardson P, Trechsel U, Widmer A, Devogelaer JP, Kaufman JM, Jaeger P, Body JJ, Bandi ML, Boell J, Di Micco R, Genazzani AR, Felsenberg D, Happ J, Hooper MJ, Ittner J, Leb G, Mallmin H, Murray T, Ortolani S, Rubinacci A, Saaf M, Samsioe G, Veruggen L, Meunier PJ (2002) Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 346:653–661PubMedCrossRefGoogle Scholar